Consensus Solventum Corporation

Stocks

SOLV

US83444M1018

Medical Equipment, Supplies & Distribution

Market Closed - NYSE 16:00:02 2026-09-18 EDT			5-day change	1st Jan Change
88.84 ^USD	+1.50%		+1.59%	+12.12%

09-09	Solventum Corporation Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 10:15 AM
08-06	Stifel Adjusts Price Target on Solventum to $100 From $90	MT

Evolution of the Average Target: Solventum Corporation

Evolution of the Target Price: Solventum Corporation

Changes in Analyst Recommendations: Solventum Corporation

4cd4d242c25898786ee.MvHbIkljdRypz7ytp25D43w7bUGF17q_w01QqJc3iWE.C9yLbhAbIEbs_4vkwzYM1ThXCznRvfTwrH0m7MB42DUFuex0cVcYUNys3w~6b24b3f407da406158295c226fb72209

Analysts' recommendations: Solventum Corporation

08-06	Stifel Adjusts Price Target on Solventum to $100 From $90	MT
08-06	KeyBanc Adjusts Price Target on Solventum to $102 From $93	MT
08-06	Mizuho Securities Adjusts Solventum Price Target to $113 From $100	MT
08-06	BTIG Research Adjusts Solventum Price Target to $95 From $91	MT
08-06	Jefferies & Co. Adjusts Solventum Price Target to $95 From $79	MT
08-06	Piper Sandler Adjusts Solventum Price Target to $105 From $92	MT
08-06	BMO Capital Adjusts Solventum Price Target to $84 From $81	MT
08-06	UBS Adjusts Price Target on Solventum to $101 From $95, Maintains Buy Rating	MT
08-06	Wedbush Adjusts Price Target on Solventum to $101 From $94, Maintains Outperform Rating	MT
07-28	UBS Upgrades Solventum to Buy From Neutral, Adjusts Price Target to $95 From $78	MT
07-13	BTIG Adjusts Solventum Price Target to $91 From $89, Maintains Buy Rating	MT
07-09	BMO Capital Initiates Coverage on Solventum With Market Perform Rating, $81 Price Target	MT
05-27	Goldman Sachs Adjusts Price Target on Solventum to $67 From $66, Maintains Sell Rating	MT
05-15	Solventum Seen Positioned for Meaningful Re-Rating Over Next 12 to 18 Months, Wedbush Says	MT
05-15	Wedbush Initiates Solventum at Outperform With $94 Price Target	MT
05-06	UBS Adjusts Price Target on Solventum to $78 From $82, Maintains Neutral Rating	MT
05-06	Analyst recommendations: AMD, KKR, PayPal Holdings, Arista Networks, and TransDigm Group.
04-27	KeyBanc Adjusts Price Target on Solventum to $92 From $99, Maintains Overweight Rating	MT
04-17	Piper Sandler Adjusts Solventum PT to $92 From $98, Maintains Overweight Rating	MT
04-13	BTIG Research Adjusts Solventum Price Target to $89 From $100, Maintains Buy Rating	MT
04-08	Goldman Sachs Adjusts Solventum Price Target to $66 From $72, Maintains Sell Rating	MT
03-24	Rothschild & Co Redburn Initiates Solventum at Sell, With $60 Price Target	MT
03-02	UBS Adjusts Solventum Price Target to $82 From $79, Maintains Neutral Rating	MT
02-27	KeyBanc Adjusts Price Target on Solventum to $99 From $97, Maintains Overweight Rating	MT
02-27	Wells Fargo Adjusts Price Target on Solventum to $83 From $86, Maintains Equalweight Rating	MT

More recommendations

Other Medical Equipment, Supplies & Distribution

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	SOLVENTUM CORPORATION					+5.72%
	ABBOTT LABORATORIES					+17.2%
	MEDTRONIC PLC					+13.79%
	CENCORA, INC.					+19.6%
	BECTON, DICKINSON AND COMPANY					+8.14%
	HOYA CORPORATION					+33.6%
	DEXCOM, INC.					+5.74%
	MEDLINE INC.					+40.96%
	WEST PHARMACEUTICAL SERVICES, INC.					+11.89%
	SARTORIUS STEDIM BIOTECH					+18.88%
	Average					+17.55%
	Weighted average by Cap.					+17.35%